Meeting
2021 Gastrointestinal Cancers Symposium
TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC).
Presenter
Masatoshi Kudo, MD, PhD
Kindai University Faculty of Medicine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Rapid Oral Abstract Session
Session Title
Rapid Abstract Session: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01217034
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 270)
DOI
10.1200/JCO.2021.39.3_suppl.270
Abstract #
270
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2018 Gastrointestinal Cancers Symposium
Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial.
Speaker: Masatoshi Kudo, MD, PhD
Videos & Slides
2023 ASCO Annual Meeting
APP Insights: Onboarding, Scope of Practice, and Maximizing Practice
Speaker: Todd Alan Pickard, FASCO
Videos & Slides
2012 Gastrointestinal Cancers Symposium
